01681.HK
Consun Pharmaceutical Group Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 13.61
−0.44%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.9B | 3.4B | 3.0B | 2.6B | 2.3B |
| Cost of Revenue | 1.5B | 750.2M | 725.1M | 668.4M | 576.7M |
| Gross Profit | 5.4B | 2.7B | 2.2B | 1.9B | 1.8B |
| Operating Expenses | |||||
| R&D Expense | 298.0M | 151.8M | 97.5M | 108.5M | 117.5M |
| SG&A Expense | 3.0B | 1.5B | 1.3B | 1.2B | 1.1B |
| General & Admin Expense | 622.8M | 445.6M | 311.9M | 315.6M | 322.5M |
| Selling & Marketing Expense | 1.6B | 1.1B | 981.6M | 852.2M | 772.0M |
| Other Expenses | (311.4M) | (204.5M) | (193.9M) | (239.6M) | (206.4M) |
| Total Operating Expenses | 2.9B | 1.5B | 1.2B | 1.0B | 1.0B |
| Cost and Expenses | 4.4B | 2.2B | 1.9B | 1.7B | 1.6B |
| Operating Income (EBIT) | 2.4B | 1.2B | 1.0B | 885.0M | 757.3M |
| Non-Operating | |||||
| Interest Income | 155.5M | 85.3M | 88.3M | 68.9M | 52.4M |
| Interest Expense | 4.5M | 4.4M | 24.9M | 21.3M | 10.9M |
| Net Interest Income | 151.0M | 80.9M | 63.4M | 47.7M | 41.5M |
| Other Non-Op Income/Expense | 26.5M | (6.0M) | (25.0M) | (21.3M) | (10.9M) |
| Non-Operating Income (excl Interest) | 90.0M | 50.3M | 70.1M | (74.9M) | 41.9M |
| EBT (Pre-Tax Income) | 2.5B | 1.2B | 1.0B | 863.7M | 746.4M |
| Income Tax Expense | 275.8M | 107.3M | 102.7M | 77.1M | 62.7M |
| Bottom Line | |||||
| Net Income | 2.2B | 1.1B | 910.5M | 784.5M | 682.9M |
| Earnings from Cont. Ops | 2.2B | 1.1B | 917.4M | 786.6M | 683.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 2.2B | 1.1B | 910.5M | 784.5M | 682.9M |
| Per Share | |||||
| Basic EPS | HK$2.56 | HK$1.26 | HK$1.11 | HK$0.98 | HK$0.86 |
| Diluted EPS | HK$2.55 | HK$1.26 | HK$1.09 | HK$0.98 | HK$0.86 |
| Revenue Per Share | HK$8.17 | HK$4.00 | HK$3.61 | HK$3.24 | HK$2.96 |
| Shares | |||||
| Basic Shares Outstanding | 841.1M | 855.1M | 821.1M | 799.2M | 790.6M |
| Diluted Shares Outstanding | 847.0M | 855.1M | 832.1M | 799.2M | 792.0M |
| Profitability Metrics | |||||
| EBITDA | 2.5B | 1.2B | 1.0B | 963.1M | 785.9M |
| D&A | 122.3M | 55.6M | 71.6M | 78.1M | 70.5M |
| EBIT | 2.4B | 1.2B | 975.0M | 885.0M | 715.4M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026